Use of Machine Learning Techniques for Serial Assessment of Systemic Inflammatory Markers in Breast Cancer Patients

Summary

Breast cancer is the most common cancer in women globally, with 2.3 million new cases diagnosed in 2020. Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer is the most prevalent subtype, comprising 69% of all breast cancers in the USA. Within the tumor immune microenvironment, a higher intensity of myeloid cell infiltration and low levels of lymphocyte infiltration have been associated with worse outcomes. Markers in peripheral blood have emerged as predictive biomarkers that can be easily obtained non-invasively and at low cost. Experiments have confirmed the relative components of these tests (such as the immune cells) directly or indirectly participated in tumour occurrence, development, and immune escape, underscoring the potential use of laboratory tests as tumour biomarkers

Conditions

• Breast Cancer

Interventions

PROCEDURE

Surgery (Mastectomy or quadrantectomy)

Surgery (mastectomy or quadrantectomy); Neoadjuvant chemotherapy

Sponsors & Collaborators

• Kansai Medical University

  collaborator OTHER

• University of Sao Paulo

  collaborator OTHER

• Kyoto University

  collaborator OTHER

• Barretos Cancer Hospital

  collaborator OTHER

• Women's College Hospital

  collaborator OTHER

• Emory University

  collaborator OTHER

• University of Campinas, Brazil

  collaborator OTHER

• Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno

  collaborator OTHER

• Instituto Nacional de Cancer, Brazil

  collaborator OTHER_GOV

• Universidade Federal do Triangulo Mineiro

  collaborator OTHER

• Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud

  collaborator OTHER

• Hospital Vall d'Hebron

  collaborator OTHER

• Mansoura University

  collaborator OTHER

• Seoul National University

  collaborator OTHER

• Federal University of São Paulo

  lead OTHER

Principal Investigators

• Afonso C Nazario, PhD · University Federal of Sao Paulo

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-08-01

Primary Completion

2024-12-31

Completion

2027-02-28

Countries

• Argentina
• Brazil
• Canada
• Egypt
• Japan
• Mexico
• South Korea
• Spain

Study Locations